Brendan O’malley Sells 9,366 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) SVP Brendan O’malley sold 9,366 shares of the company’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $5.39, for a total value of $50,482.74. Following the sale, the senior vice president owned 350,763 shares of the company’s stock, valued at $1,890,612.57. This trade represents a 2.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Abeona Therapeutics Stock Up 1.7%

ABEO stock opened at $5.41 on Friday. The stock’s fifty day simple moving average is $6.36 and its two-hundred day simple moving average is $5.92. The company has a current ratio of 6.73, a quick ratio of 6.65 and a debt-to-equity ratio of 0.09. Abeona Therapeutics Inc. has a 1-year low of $3.93 and a 1-year high of $7.54. The stock has a market cap of $277.42 million, a P/E ratio of 7.73 and a beta of 1.42.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share for the quarter, topping the consensus estimate of ($0.39) by $2.10. The business had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $21.71 million. Analysts expect that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Oppenheimer boosted their price objective on Abeona Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a research report on Friday, August 15th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research report on Monday, August 18th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Abeona Therapeutics in a research report on Saturday, September 27th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $19.50.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Trexquant Investment LP lifted its position in shares of Abeona Therapeutics by 74.1% during the 1st quarter. Trexquant Investment LP now owns 119,274 shares of the biopharmaceutical company’s stock valued at $568,000 after buying an additional 50,758 shares during the last quarter. Wellington Management Group LLP purchased a new stake in Abeona Therapeutics during the 4th quarter worth about $520,000. Goldman Sachs Group Inc. lifted its holdings in Abeona Therapeutics by 49.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock worth $954,000 after purchasing an additional 66,422 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in Abeona Therapeutics during the 4th quarter worth about $67,000. Finally, Newtyn Management LLC lifted its holdings in Abeona Therapeutics by 26.3% during the 1st quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company’s stock worth $2,285,000 after purchasing an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.